Paraganglioma Clinical Trial
Official title:
A Phase 2 Study of Pazopanib (GW786034) in Patients With Advanced and Progressive Malignant Pheochromocytoma or Paraganglioma
This phase II trial studies how well pazopanib hydrochloride works in treating patients with advanced or progressive malignant pheochromocytoma or paraganglioma. Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
PRIMARY OBJECTIVES:
I. To assess the anti-tumor activity (in terms of the tumor response rate using the Response
Evaluation Criteria in Solid Tumors [RECIST] criteria) of pazopanib (pazopanib hydrochloride)
(GW786034) in patients with advanced malignant pheochromocytomas and paragangliomas.
SECONDARY OBJEC TIVES:
I. To assess safety profile of pazopanib. II. To assess duration of tumor response. III. To
assess time to treatment failure. IV. To assess progression-free survival time. V. To assess
overall survival time.
TERTIARY OBJECTIVES:
I. For patients with secretory tumors, to examine changes in urinary catecholamine and/or
metanephrine levels.
II. For patients with secretory tumors, to examine whether pazopanib-induced changes in
urinary catecholamine and/or metanephrine levels during the first cycle of treatment may be
associated with objective tumor response.
III. To examine associations between tumor response and somatic mutational status in archived
tumors, or germline mutational status in patient's peripheral blood mononuclear cells,
(presence of succinate dehydrogenase complex subunit D [SDHD], succinate dehydrogenase
complex subunit B [SDHB], ret proto-oncogene [RET], von Hippel-Lindau tumor suppressor [VHL],
neurofibromatosis type-1).
IV. To examine associations between tumor response and tumor expression levels of angiogenic
and vascular markers including hypoxia inducible factor 1, alpha (HIF-1a), vascular
endothelial growth factor receptor (VEGF-R) (total and phospho-) and microvessel density in
archival tumor tissue.
IV. To examine whether the extent of tumor response/regression may be correlated with plasma
pazopanib (GW786034) concentration achieved after the third cycle (first cycle after run-in
cycles) of pazopanib (GW786034) therapy.
OUTLINE:
Patients receive pazopanib hydrochloride orally (PO) once daily (QD) on days 1-28 (days 1-14
of courses 1 and 2). Courses repeat every 28 days in the absence of disease progression or
unacceptable toxicity.
Patients undergo urine and blood sample collection at baseline and periodically during study
for correlative studies.
After completion of study therapy, patients are followed up every 3-6 months for up to 5
years.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04081701 -
68-Ga DOTATATE PET/MRI in the Diagnosis and Management of Somatostatin Receptor Positive CNS Tumors.
|
Phase 4 | |
Recruiting |
NCT05636618 -
Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Neuroendocrine Tumors
|
Phase 1/Phase 2 | |
Terminated |
NCT05948137 -
F-18 FDOPA PET/CT Versus I-123 MIBG Scintigraphy With SPECT/CT for the Diagnosis of Pheochromocytoma and Paraganglioma
|
||
Recruiting |
NCT05069220 -
18F-MFBG PET/CT in the Evaluation of Neural Crest Tumor
|
Early Phase 1 | |
Recruiting |
NCT04573816 -
Development of a Tele-monitoring Program for Patients Undergoing Surgery for Pheochromocytoma and / or Paraganglioma
|
||
Active, not recruiting |
NCT04400474 -
Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CABATEN Study
|
Phase 2 | |
Not yet recruiting |
NCT06045260 -
"Receptor Radionuclide Therapy With 177Lu-DOTATOC
|
Phase 2 | |
Withdrawn |
NCT01941849 -
Phase I Trial of Vandetanib Combined With 131I-mIBG to Treat Patients With Advanced Phaeochromocytoma and Paraganglioma
|
Phase 1 | |
Completed |
NCT01204476 -
Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma
|
Phase 1 | |
Completed |
NCT01967576 -
Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma
|
Phase 2 | |
Recruiting |
NCT03160274 -
Genetic Analysis of Pheochromocytomas, Paragangliomas and Associated Conditions
|
||
Recruiting |
NCT03206060 -
Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma
|
Phase 2 | |
Not yet recruiting |
NCT04788927 -
Development of a Predictive Model for the Risk of Metastatic Disease in PPGLs, a Retrospective Cohort Study
|
||
Recruiting |
NCT04119024 -
Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
|
Phase 1 | |
Completed |
NCT01022515 -
Specificity of Elevated Plasma EM66 Levels in Pheochromocytoma
|
N/A | |
Completed |
NCT00188019 -
Hereditary Paraganglioma: Evaluation of Screening Methods to Detect Tumors in SDH Positive Carriers
|
N/A | |
Recruiting |
NCT06155734 -
Fluorescence Guided Minimally-Invasive Resection Of Abdominal Paragangliomas Using Indocyanine Green
|
||
Recruiting |
NCT04017104 -
Dynamic Whole Body Positron Emission Tomography/Computed Tomography Imaging
|
||
Recruiting |
NCT04891081 -
Plasma Metanephrines in Patients With Cyanotic and Acyanotic Congenital Heart Disease
|
||
Recruiting |
NCT03344016 -
Multicenter Pheochromocytoma and Paraganglioma Evaluation
|
N/A |